Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D01QQC
|
|||
Former ID |
DIB004820
|
|||
Drug Name |
Hematopoietic stem cell gene therapy
|
|||
Synonyms |
Hematopoietic stem cell gene therapy (Wiskott-Aldrich syndrome)
Click to Show/Hide
|
|||
Indication | Wiskott-Aldrich syndrome [ICD-11: 3B62.0; ICD-10: D82.0] | Phase 1/2 | [1] | |
Company |
Advantagene
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Wiskott-Aldrich syndrome protein (WAS) | Target Info | Modulator | [2] |
KEGG Pathway | Chemokine signaling pathway | |||
Adherens junction | ||||
Fc gamma R-mediated phagocytosis | ||||
Regulation of actin cytoskeleton | ||||
Bacterial invasion of epithelial cells | ||||
Pathogenic Escherichia coli infection | ||||
Shigellosis | ||||
Salmonella infection | ||||
Choline metabolism in cancer | ||||
Panther Pathway | T cell activation | |||
Pathway Interaction Database | TCR signaling in naï | |||
Reactome | Generation of second messenger molecules | |||
Regulation of actin dynamics for phagocytic cup formation | ||||
RHO GTPases Activate WASPs and WAVEs | ||||
WikiPathways | TCR Signaling Pathway | |||
G13 Signaling Pathway | ||||
Regulation of Actin Cytoskeleton | ||||
Human Complement System | ||||
Fcgamma receptor (FCGR) dependent phagocytosis | ||||
Pathogenic Escherichia coli infection | ||||
TCR signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT02559830) Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy. | |||
REF 2 | Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Curr Opin Mol Ther. 2006 Oct;8(5):390-5. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.